Pressure BioSciences, Inc. · OTC:PBIO

Pressure BioSciences — Investor Presentation (March 2012)

27 slides from Pressure BioSciences's investor presentation, Mar 14, 2012

  1. Slide 1: Investor Presentation

    Investor Presentation Pressure BioSciences, Inc. ((NASDAQ CM: PBIO)) Discovery Starts with Sample Preparation™ March 14,, 2012

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation Thi t ti may contain t i fforward d llooking ki statements t t t that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations operations. These statements are neither a

  3. Slide 3: Key Investment Highlights

    Key Investment Highlights • Pressure Cycling Technology (PCT): Powerful, Enabling, Patented • $6 Billion Billi M Market k tOOpportunity: t it Bi Biological l i lS Sample l PPreparation ti • PCT Products Offer Significant Advantages Over Competitive Methods • Focus F on Sample S l PPreparation: ti Bi

  4. Slide 4: Company Background

    Company Background • Formed Sept 2004 - Sale of Boston Biomedica (BBII) ( ) • Started Significant Operations in 2006 • NASDAQ CM: PBIO • Thirteen (13) Full-time Employees • S Strong Management Team and Board off Directors • Focused on the Development and Commercialization of C PCT-based Instruments

  5. Slide 5: Experienced Senior Management & Board

    Experienced Senior Management & Board Management • M Mr. Ri Richard h d T. T Schumacher, S h h President P id t & CEO Boston Biomedica (CEO); Panacos Pharma (President); Center for Blood Research (CBR Labs - Harvard Medical School) -General Manager • Dr. Edmund Y. Ting, g, Senior Vice President of E

  6. Slide 6: Past Accomplishments – CEO and Chairman

    Past Accomplishments – CEO and Chairman Company Role Top Market Cap Outcome Schumacher Pressure BioSciences (Nasdaq PBIO) Founder Founder, CEO CEO, Director Boston Biomedica (Nasdaq BBII) Founder, CEO, Director ~$120 million Sold Panacos Pharma (Nasdaq PANC) Co-Founder, Director ~$650 million Sold T

  7. Slide 7: Value Proposition – Sample Prep Market

    Value Proposition – Sample Prep Market • Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Development of New Diagnostics & Therapeutics • Sample Preparation is Required Prior to Virtually All Analyses • Current Sample Preparation Methods are Highly Inadequate: bottleneck •

  8. Slide 8: Pressure Cycling Technology (PCT)

    Pressure Release Cycling yBiomolecules Important p g Technology ygy by (PCT) ( Lysis Cell y ) 8

  9. Slide 9: Sample Input Quality = Sample Result Quality

    Sample Input Quality = Sample Result Quality Scientific research can be broken down to three key elements: sample preparation, analysis, & data reduction/interpretation “Discovery Starts with Sample Preparation” 9

  10. Slide 10: Competitive Landscape

    Competitive Landscape Mostly Commodity Products Through Catalogue Sales • Mortar & Pestle • Dounce homogenizer (glass on glass) • Potter-Elvenhjem homogenizer (Teflon on glass) • Enzymatic Digestion • Polytron shearing homogenizers • Blenders • Bead Beating • Sonication • Repeated Freeze/Thaw cycles

  11. Slide 11: PCT Sample Preparation System

    PCT Sample Preparation System Barocycler™ NEP2320 Barocycler™ NEP3229 PULSE Tube MicroTubes PCT-dependent Kits 11

  12. Slide 12: Selected Marquee Customers (40 of 150)

    Selected Marquee Customers (40 of 150) • Amgen • Thermo Fisher • Biogen • Promega Corporation • Lillyy • Battelle Memorial Institute • Novartis • Harvard Medical School • Monsanto • Harvard School of Public Health • BM Squibb • Rockefeller University • Merck • Universityy of New Hampshire p • Takeda

  13. Slide 13: Current PCT Products & Product Pipeline

    Current PCT Products & Product Pipeline • PCT Sample Preparation System 2012: Aggressive (Barocycler NEP3229 & NEP2320) Commercialization • The PCT Shredder SG3 Just Released • Barocycler HUB440 Just Released • FFPE System – proteins, DNA/RNA 2012 • PCT-based HT (48 - 384 well format) 2013 • Xstream

  14. Slide 14: PCT Sample Preparation System

    PCT Sample Preparation System Barocycler™ NEP2320 Barocycler™ NEP3229 PULSE Tube MicroTubes PCT-dependent Kits 14

  15. Slide 15: The Shredder SG3

    Product Pipeline (2011 Release) The Shredder SG3 Low Shear, Mechanical, Homogenization Device • Long lasting lithium rechargeable batteries • Paddle for convenient pressure setting • Pressure levels: 15, 30, 45 lbs. Force • Uses PCT PULSE and Shredder Tubes • Heavy Duty, Robust Driver 15

  16. Slide 16: The Barocycler HUB440

    Product Pipeline (2011 Release) The Barocycler HUB440 Hi h Pressure High P Generator G t • Compact p • Portable • Versatile • Manual or Computer Controlled • Pressures to 58Kpsi State-of-the-Art High Pressure Generator for Multiple Bioscience Applications AVAILABLE Q3 2011 16

  17. Slide 17: The Barocycler NEP-FFPE

    Product Pipeline (2012 Release) The Barocycler y NEP-FFPE • 1 Billion Stored Samples WW • 6x More Non-redundant Proteins from FFPE Aorta Dr. J. Van Eyk, et al., J. Hopkins • 2x More Unique Proteins from FFPE Mouse Liver Dr. C. Fowler, et al., AFIP PCT-enhanced Protein Extraction from F li Fi d P For

  18. Slide 18: XstreamPCT Digestion Module

    Product Pipeline (2013 Release) XstreamPCT™ Digestion Module A t Automated, t d In-line, I li On-demand O d d PCT-enhanced PCT h d Digestion Di ti • Significantly Reduced Protein Digestion Time • Increased Membrane Protein Recovery • Rapid & Less Costly De-glycosylation • Excellent Reproducibility T

  19. Slide 19: The Barocycler HT Multiwell (48/96/384)

    Product Pipeline (2013 Release) The Barocycler HT Multiwell (48/96/384) Process 48, 96, or 384 Samples with the • Safety S f • Speed • Quality • Versatility • Reproducibility of PCT For High Throughput PCT-enhanced Biomolecule Extraction & Accelerated Enzymatic Digestion AVAILABLE 2013 19

  20. Slide 20: Financial Data

    Financial Data Historical Revenue Data • 2008 $ 852,000 • 2009 $1,245,000 • 2010 $1,340,000 • 2011 $ 988,000 Selected Data Through December 31, 31 2011 • Cash/Cash Equivalents ~$0.2 million • Inventory ~$1.1 million • Debt ((unsecured)) $ 0.4 million • Total Assets ~$1.9 million • Total Liabilities

  21. Slide 21: Capitalization Table

    Capitalization Table As of February 24, 2012 I C In Common StStockkE Equivalents) i l t ) Description Number Common Shares Outstanding 8,385,090 Convertible Preferred Stock C 880,980 Convertible Preferred Stock D 553,847 Total Common Stock Equivalents 9,819,917 Warrants (Weighted Average Strike Pric

  22. Slide 22: PBI Sample Preparation Focus Areas

    PBI Sample Preparation Focus Areas Biomarker Discovery Dr. Andreas Huhmer – Thermo Fisher Scientific …advantages of speed and quality using PCT in mass spec workflow Dr. Michael Alterman – Tumor Vaccines and Biotechnology Branch, CBER, FDA …improved influenza vaccine quality using PCT in mass spec w

  23. Slide 23: Recent News of Interest

    Recent News of Interest 2012 Collaboration with Dr Dr. Henry C C. Lee and the HCL Institute of Forensic Science Dr. W. Hubbell (UCLA) Presents Data Citing Proteomics Enhancement with PCT European Sales Reach Expanded with Distribution Agmt for Benelux Countries PBI Reports 2011 Financial Results – 2

  24. Slide 24: Professor Wayne Hubbell - UCLA

    Professor Wayne Hubbell - UCLA Distinguished Professor of Chemistry & Biochemistry, and Jules Stein Professor at UCLA "Protein Protein flexibility is the new frontier in understanding protein function and regulation. The study of proteins under pressure has great ability to reveal salient features o

  25. Slide 25: Dr. Henry C. Lee

    Dr. Henry C. Lee Professor of Forensic Science and founder of the Forensic Science Program at the University of New Haven; founder of the HC Lee Institute of Forensic Sciences; and f former C Commissioner i i off Public P bli Safety for the State of Connecticut. ““We are excited about this opportuni

  26. Slide 26: 2012 Expected Drivers

    2012 Expected Drivers • Aggressive Commercialization Program • Expansion of Distribution Network (3 to ~20 countries) • Expansion p of PBI Sales (3 ( to 10)) & Marketing g (1 ( to 4)) Team • Expansion of Strategic Partners (2 to 5, or more) • Expected Completion of Significant Funding (up to 2 years

  27. Slide 27: Key Investment Highlights

    Key Investment Highlights • Pressure Cycling Technology (PCT): Powerful, Enabling, Patented • $6 Billion Billi M Market k tOOpportunity: t it Bi Biological l i lS Sample l PPreparation ti • PCT Products Offer Significant Advantages Over Competitive Methods • Focus F on Sample S l PPreparation: ti Bi

Pressure BioSciences — Investor Presentation (March 2012) on 6ix